LncRNA Information
ID EL0799 Name lncRNA-ATB Aliases N/A
Species Homo sapiens Chromosome 14 Start site 19858667
End site 19941024 Chain N/A Exon NO. N/A
Assembly N/A Class N/A NCBI accession N/A
Ensembl N/A Sequence N/A

Disease Method Sample Expression pattern Dysfunction type Description PMID Source
hepatocelluar carcinoma immunohistochemistry quantitative RT-PCR analysis keloid tissue and keloid fibroblasts N/A N/A lncRNA-ATB governs the autocrine secretion of TGF-β2 in KFs 27090737
hepatocelluar carcinoma microarray, qPCR etc. HCC tissue, cell lines (SMMC-7721) up-regulated regulation Thus, these findings suggest that?lncRNA-ATB, a mediator of TGF-β signaling, could predispose HCC patients to metastases and may serve as a potential target for antimetastatic therapies. 24768205 LncRNADisease Lnc2Cancer
colorectal cancer qPCR etc. CRC tissue up-regulated N/A High lncRNA-ATB expression was significantly associated with greater tumor size, depth of tumor invasion, lymphatic invasion, vascular invasion, and lymph node metastasis. Additionally, levels of lncRNA-ATB expression were significantly higher in patients with hematogenous metastases. 25750289 LncRNADisease Lnc2Cancer
gastric cancer qPCR etc. gastric cancer tissue, cell lines (MKN1, MKN7, MKN28, MKN45, MKN74 etc.) differential expression interaction The high lncRNA-ATB group experienced a lower overall survival rate compared with the low lncRNA-ATB group, and multivariate analysis indicated that lncRNA-ATB was an independent prognostic factor (hazard ratio 3.50; 95 % CI 1.73-7.44; p = 0.0004).LncRNA-ATB plays an important role in EMT to promote invasion and metastasis through the TGFb/miR-200s/ZEB axis, resulting in a poor prognosis in GC.LncRNA-ATB is a novel biomarker of lncRNA, indicative of a poor prognosis in GC patients. 25986864 Lnc2Cancer
pancreatic cancer qPCR etc. pancreatic cancer and paired adjacent normal pancreatic tissues, cell lines (HPDE6c-7) down-regulated expression We found that lncRNA-ATB expression was decreased in pancreatic cancer tissues and pancreatic cancer cell lines. Low lncRNA-ATB expression levels were significantly correlated with lymph node metastases (yes vs. no, P = 0.009), neural invasion (positive vs. negative, P = 0.049), and clinical stage (early stage vs. advanced stage, P = 0.014). Moreover, patients with low lncRNA-ATB expression levels exhibited markedly worse overall survival prognoses (P < 0.001). Multivariate analysis indicated that decreased lncRNA-ATB expression was an independent predictor of poor prognosis in pancreatic cancer patients (P = 0.005). 26482611 Lnc2Cancer
colon cancer qPCR etc. colon cancer tissues up-regulated interaction LncRNA-ATB was upregulated in colon cancer tissues compared with adjacent mucosa. LncRNA-ATB levels were also higher in metastatic cancer tissues. Among the three highly invasive colon cancer cell lines, lncRNA-ATB levels were relatively higher with concurrent low levels of E-cad compared with levels in the three low-invasive cell lines. LncRNA-ATB expression correlated with pN stage and AJCC stage. Striking differences were observed in overall survival and disease-free survival in cases with both high lncRNA-ATB expression and low E-cad expression. Reduction of lncRNA-ATB increased expression of epithelial markers E-cad, ZO-1, and decreased expression of mesenchymal markers ZEB1 and N-cadherin (N-cad), and significantly influenced colon cancer cell progression. Plasma lncRNA-ATB was upregulated in colon cancer patients one month after surgery. 26487301 Lnc2Cancer

Interaction target Level of interaction Type of interaction Description PMID Source
SB431542 RNA-RNA regulation Treatment with TGF-β in GC cell lines resulted in morphological EMT changes, upregulation of lncRNA-ATB and ZEB1, and downregulation of miR-200c and CDH1. SB431542 reduced lncRNA-ATB expression 25986864
E-cadherin RNA-DNA regulation Long non-coding RNA-activated by TGF-β may act on colon tumorigenesis by suppressing E-cad expression and promoting EMT process 26487301